Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
What's Going On With Black Diamond Therapeutics Stock Tuesday?
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
BDTX Shares Gain 11% in a Week: Here's What You Should Know
Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Implied Volatility Surging for Black Diamond Therapeutics Stock Options
BDTX Stock: Neutral Zacks Rank, $4 Target, and What Must Go Right
BDTX and the CNS-Active EGFR Trend: Why C797S Is the Prize
Black Diamond's Lead Drug Silevertinib: Key Data, Catalysts, and Risks
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
Why Is Black Diamond (BDTX) Up 19.3% Since Last Earnings Report?
BDTX and Brain Metastases: Why CNS Activity Could Matter in 2026
Black Diamond Stock: Weighing Catalysts vs. Concentration
BDTX: What Silevertinib Data Say About EGFR NSCLC Upside
Black Diamond Therapeutics: Market Is Yawning About These Data, But I See Opportunity
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year?
What Makes Black Diamond (BDTX) a New Strong Buy Stock
New Strong Buy Stocks for January 9th
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Comparing Iovance Biotherapeutics (NASDAQ:IOVA) & Black Diamond Therapeutics (NASDAQ:BDTX)
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)
Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout
Black Diamond Therapeutics, Inc. (BDTX) Hits Fresh High: Is There Still Room to Run?
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings?
BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now?
Can NSCLC Drug Silevertinib Drive Sustainable Growth for BDTX?
BDTX Stock Hits 52 Week High: Is There More Room for Growth?
Black Diamond Therapeutics, Inc. (BDTX) Hit a 52 Week High, Can the Run Continue?
Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?
BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy?
Has Black Diamond Therapeutics (BDTX) Outpaced Other Medical Stocks This Year?
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?
BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?
Black Diamond Therapeutics: A Potential First-Line In NSCLC Trading At Cash